Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3

1 clinical trials · Condition

Record	Firm	Date
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (NCT02113800)	AIO-Studien-gGmbH	2015-08-01

Every clearance here is in the API, with alerts when new ones post.